LXH254 Combination for Non-Small Cell Lung Cancer

Recruiting in Palo Alto (17 mi)

+39 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: Novartis Pharmaceuticals

No Placebo Group

Breakthrough Therapy

Trial Summary

What is the purpose of this trial?

This trial is testing a new drug (LXH254) combined with other existing drugs to find a safe and effective dose for cancer patients who need new treatment options. The drugs work by blocking signals that cancer cells use to grow.

Eligibility Criteria

This trial is for adults with advanced lung cancer (NSCLC) or skin melanoma that's worsened after standard treatment, or when no suitable standard treatment exists. Participants must have specific mutations in their tumors and be physically able to perform daily activities with some limitations.

Inclusion Criteria

My cancer is advanced non-small cell lung cancer or skin melanoma.

All patients participating in this clinical trial must have progressed following standard therapy or, in the opinion of the Investigator, no effective standard therapy exists, is tolerated, appropriate or is considered equivalent to study treatment

My cancer has a KRAS, BRAF, or NRAS mutation.

See 1 more

Exclusion Criteria

I have had 3 or fewer previous cancer treatments.

I have had specific previous cancer treatments and my cancer has certain genetic mutations.

I have Gilbert's syndrome or a similar inherited liver condition.

See 4 more

Treatment Details

Interventions

LTT462 (Kinase Inhibitor)
LXH254 (Kinase Inhibitor)
Ribociclib (Kinase Inhibitor)
Trametinib (Kinase Inhibitor)

Trial OverviewThe study tests the safety and best dose of LXH254 combined with either LTT462, trametinib, or ribociclib. It aims to find out how well patients tolerate these combinations and establish a recommended dosage regimen.

Participant Groups

3Treatment groups

Experimental Treatment

Group I: LXH254+TrametinibExperimental Treatment2 Interventions

Group II: LXH254+RibociclibExperimental Treatment2 Interventions

Group III: LXH254+LTT462Experimental Treatment2 Interventions